Morrison Jodie Pope
SEC-identified person · CIK 1618247 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Q32 Bio Inc. QTTB | Director · CEO | filed 2024–2026 |
| Verve Therapeutics, Inc. VERV | Director | filed 2024–2025 |
| Rein Therapeutics, Inc. RNTX | Director | filed 2017–2022 |
| Akebia Therapeutics, Inc. AKBA | Director | filed 2018–2019 |
| Keryx Biopharmaceuticals INC KERX | Director · Interim CEO | filed 2016–2018 |
| Tokai Pharmaceuticals Inc TKAI | Director · President and CEO | filed 2014–2017 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.